Sugi Predict

Sugi Predict / Compounds / SCHEMBL21491203

SCHEMBL21491203

SCHEMBL21491203

COC(=O)c1ccc(OC)c(C2COCCCN2c2cc(C)nc(N)n2)c1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CRHBP P24387 2/20 0.37
▸ CRHR2 Q13324 2/20 0.37
▸ F10 P00742 1/20 0.37
▸ MTOR P42345 4/20 0.36
▸ GLA P06280 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ ALOX15 P16050 2/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ MGLL Q99685 1/20 0.34
▸ RPS6KB1 P23443 1/20 0.34
▸ MAPT P10636 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31472382 1.00 CRHBP (0.37) CRHBPCRHR2F10MTORGLA
SCHEMBL29456319 1.00 CRHBP (0.37) CRHBPCRHR2F10MTORGLA
SCHEMBL31472363 1.00 CRHBP (0.37) CRHBPCRHR2F10MTORGLA
SCHEMBL21516870 0.93 CRHBP (0.37) CRHBPCRHR2F10MTORGLA
SCHEMBL21491419 0.92 CRHBP (0.38) CRHBPCRHR2F10MTORKMT2A
SCHEMBL21491307 0.91 F10 (0.39) CRHBPCRHR2F10MTORKMT2A
SCHEMBL21491309 0.91 F10 (0.39) CRHBPCRHR2F10MTORKMT2A
SCHEMBL30952543 0.91 F10 (0.39) CRHBPCRHR2F10MTORKMT2A
SCHEMBL31472407 0.91 F10 (0.39) CRHBPCRHR2F10MTORKMT2A
SCHEMBL21491448 0.91 F10 (0.39) CRHBPCRHR2F10MTORKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188070-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2025-06-12 — — US disclosed
CN-112236428-B Antiproliferative compounds and uses thereof 默克专利股份有限公司 2025-04-01 — — CN disclosed
US-12195453-B2 Antiproliferation compounds and uses thereof MERCK PATENT GMBH (DE) 2025-01-14 — — US disclosed
EP-4043460-B1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2024-06-05 — — EP disclosed
US-20230150993-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2023-05-18 — — US disclosed
US-20230150993-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2023-05-18 — — US disclosed
US-20230150993-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2023-05-18 — — US disclosed
US-11440907-B1 Antiproliferation compounds and uses thereof MERCK PATENT GMBH (DE) 2022-09-13 — — US disclosed
EP-4043460-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF Merck Patent GmbH (DE) 2022-08-17 — — EP disclosed
EP-4043460-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF Merck Patent GmbH (DE) 2022-08-17 — — EP disclosed
EP-3784666-B1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2022-03-16 — — EP disclosed
EP-3784666-B1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2022-03-16 — — EP disclosed
EP-3784666-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF Merck Patent GmbH (DE) 2021-03-03 — — EP disclosed
CN-112236428-A Antiproliferative compounds and uses thereof 默克专利股份有限公司 2021-01-15 — — CN disclosed
US-10815225-B2 Antiproliferation compounds and uses thereof MERCK PATENT GMBH (DE) 2020-10-27 — — US disclosed
US-10815225-B2 Antiproliferation compounds and uses thereof MERCK PATENT GMBH (DE) 2020-10-27 — — US disclosed
US-20190322658-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-10-24 — — US disclosed
US-20190322658-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-10-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190322658-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MKI67, MCL1, CCNI CRHBP 4181/4885CRHR2 4068/4885F10 4179/4885
US-12195453-B2 Antiproliferation compounds and uses thereof MKI67, MCL1, CCNI CRHBP 4181/4885CRHR2 4068/4885F10 4179/4885
US-11440907-B1 Antiproliferation compounds and uses thereof MKI67, MCL1, CCNI CRHBP 4181/4885CRHR2 4068/4885F10 4179/4885
US-20230150993-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MKI67, MCL1, CCNI CRHBP 4181/4885CRHR2 4068/4885F10 4179/4885
US-10815225-B2 Antiproliferation compounds and uses thereof MKI67, MCL1, CCNI CRHBP 4181/4885CRHR2 4068/4885F10 4179/4885
US-20250188070-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MKI67, MCL1, CCNI CRHBP 4181/4885CRHR2 4068/4885F10 4179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.